Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Mateo, J, Porta, N, Bianchini, D et al. (38 more authors) (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 21 (1). pp. 162-174. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Mateo, J
  • Porta, N
  • Bianchini, D
  • McGovern, U
  • Elliott, T
  • Jones, R
  • Syndikus, I
  • Ralph, C https://orcid.org/0000-0001-5581-2987
  • Jain, S
  • Varughese, M
  • Parikh, O
  • Crabb, S
  • Robinson, A
  • McClaren, D
  • Birtle, A
  • Tanguay, J
  • Miranda, S
  • Figueiredo, I
  • Seed, G
  • Bertan, C
  • Flohr, P
  • Ebbs, B
  • Rescigno, P
  • Fowler, G
  • Ferreira, A
  • Riisnaes, R
  • Pereira, R
  • Curcean, A
  • Chandler, R
  • Clarke, M
  • Gurel, B
  • Crespo, M
  • Nava Rodrigues, D
  • Sandhu, S
  • Espinasse, A
  • Chatfield, P
  • Tunariu, N
  • Yuan, W
  • Hall, E
  • Carreira, S
  • de Bono, JS
Copyright, Publisher and Additional Information: © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Dates:
  • Published: 1 January 2020
  • Accepted: 4 October 2019
  • Published (online): 2 December 2019
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 08 Nov 2019 12:52
Last Modified: 16 Jan 2020 14:43
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S1470-2045(19)30684-9

Share / Export

Statistics